NET Cancer webinar series

NET Cancer webinar series

Webinar Series with NET Cancer specialists

A series of webinars from NET Cancer specialist. Produced by CNETS SG at Asia Pacific Neuroendocrine Tumor Society (APNETS) conference. Many of the talks are of particularly interest to NET Cancer advocates, and also to patients and caregivers. View presentations from; Marianne Pavel, Rodney Hicks, Sugandha Dureja, Frank Ulrich Pape, David Tai, Kjell Oberg and many more.

Thanks to Carcinoid & Neuroendocrine Tumor Society of Singapore, CNETS SG, for sharing and producing the webinar. Also thanks to Ipsen Pharma for their support creating these videos.

Hallmarks of NETs Development

Presentation by Prof. Kjell Oberg, Uppsala University, Sweden. Dr Oberg is Professor of Endocrine Oncology and has a long list of distinguished appointments.

Staging G3 NEC using Ki67 grade.

Presentation by David Tai Wai-Meng. Dr David Tai is a Consultant Medical Oncologist at National Cancer Centre Singapore. His area of interest is in gastrointestinal cancers and early developmental therapeutics.

Debate Over PRRT Versus ‘Medical Treatment’

This debate about 1st-line therapeutic options is between Dr. Marianne Pavel and Dr Rodney J. Hicks. What is described by Dr Pavel as ‘medical treatment’ are systemic chemo and biologic combinations generally reserved for G2 and G3 patients. Dr Hicks is highlighting that, contrary to popular perception of PRRT being exclusively for G1 patients, many G2 and G3 patients also benefit significantly. He calls this the ‘sweet spot’ for PRRT. Dr Hicks also recommends combined therapy for such patients. This is a very controversial topic, as you will see in the audience Q&A.

Radiological Theranostics in NETs

Presentation by Sugandha Dureja. Dr.Dureja is a dynamic nuclear medicine physician and thyroid specialist. She is amongst the first Indian Specialists with fellowship training in Theranostics, PRRT and Molecular Radiotherapy from Germany and extensive experience in PET-CT.

Immunotherapy for NETs

Presentation by Dr Kjell Oberg of Upsalla University Hospital, Sweden. Dr Oberg became an immunotherapy pioneer in 2013 when he and Upsalla colleagues announced their Oncolytic Virus research and with journalist Alexander Masters launched a crowd-sourced fundraising effort. The team is currently conducting phase I/II clinical trials of their oncolytic virus candidate – AdVince

Future of NETs Therapy

This Novartis Tea Symposium is the second of a two-part presentation, this part on the future of NETs therapy. Presentation by Marianne Pavel. Dr Pavel is a Senior Physician and Leader of the Section for Neuroendocrine Tumors in the Department of Hepatology and Gastroenterology at the Charité-Universitätsmedizin Berlin, Germany. This presentation is sponsored by Novartis Pharmaceuticals.